{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-006247","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.414060+00:00","generated_at":"2026-05-30T02:03:55.039313+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Compass Therapeutics Q3 2024 net loss $10.5M ($0.08/share); cash $135M","bullets":["Net loss $10.5M vs $10.0M in Q3 2023; diluted EPS $0.08 unchanged.","Cash and marketable securities $135M as of Sep 30, 2024; runway into Q1 2027.","Phase 2/3 CTX-009 BTC trial fully enrolled; top-line data expected end of Q1 2025.","CTX-009 Phase 2 in DLL4-positive CRC second-line planned for mid-2025.","CTX-471 Phase 2 trial in NCAM-expressing tumors planned for mid-2025 based on biomarker data."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-006247","json":"https://secwatch.observer/filing/0001171843-24-006247.json","markdown":"https://secwatch.observer/filing/0001171843-24-006247.md","text":"https://secwatch.observer/filing/0001171843-24-006247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324006247/0001171843-24-006247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324006247/f8k_111224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:03:55.039313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}